Check out your Company Bowl for anonymous work chats.
Verily Wastewater, a wastewater-based epidemiology, can accurately and proactively measure the concentration of viral and bacterial DNA and RNA for 13+ pathogens in wastewater — in near real time. Most recently, in response to H5N1 cases, Verily scientists rapidly developed an assay to detect H5 in wastewater and tested areas in Texas where dairy cattle had tested positive. We’re currently testing for H5 at more than a hundred wastewater sites in over 40 states across the country, in partnership with WastewaterSCAN. Our work suggests that proactive wastewater surveillance testing can serve as a public health monitoring tool by detecting new and emerging animal pathogens with zoonotic potential, like H5N1.
Connect with the Verily team at AHIP 2024, and listen in with our leadership. Verily Chief Clinical Officer and Head of Health Equity, Vindell Washington, MD, MS, along with co-speakers Kendell LeBray, MPH, Kelli Tice, MD, and LaShawn McIver, MD, MPH, will discuss the steps for sustainability and growth for health equity initiatives, and the impact of politics on health equity and DEI programs. Attend this compelling session on Tuesday, June 11th at 4:30 pm PT.
U.S. adults reporting they are depressed or receiving treatment for depression. By understanding their experiences across time and in a real-world setting we can pave the way for more effective treatments. Learn about the ‘My Mental Health Journey’ longitudinal registry study that we worked with Otsuka Pharmaceutical Companies (U.S.) to launch. The aim is to advance research in depression and mental health to support the development of more precise treatment options.
Verily is looking forward to this year’s AHIP event, June 11-13 in Las Vegas, to connect on what’s new in healthcare with health plan leaders, including our upcoming news... Join us at booth #1232 to hear Verily’s latest planned addition to our care portfolio, as we deepen our commitment to supporting members living with chronic conditions.
Psychiatric trials face the lowest success rates among major therapeutic areas across all clinical trial phases. Only 6.2% of compounds entering psychiatric clinical development get regulatory approval, which leads to lower investment in new treatments. Verily leaders and scientists lay out how digital measures, such as those captured through a wearable or smartphone device, can help address three central challenges in psychiatric trials: ➡️ Psychiatric heterogeneity - by differentiating between patient subtypes via predictive digital biomarkers of treatment response ➡️ Endpoint subjectivity - by providing more objective measures of patient functioning that are related to meaningful aspects of health and that are sensitive to treatment response ➡️ High placebo response rates - by identifying patients that are less likely to respond to placebo via predictive digital biomarkers of placebo response Overall, our team discusses the potential for using digital biomarkers to de-risk psychiatry trials and accelerate treatments and cures for mental health conditions. We are proud to advance this space with the use of Verily Study Watch to capture digital measures in clinical trials across a variety of therapeutic areas, including psychiatry.
We’re wrapping up a month of activities to celebrate Asian Pacific American Heritage Month. Thank you to our Hyphen ERG for bringing Veeps together and hosting dance workshops, game nights, and an internal talk with Asian leaders at Verily. So fun, inspiring and educational!
The study detailing our work with WastewaterSCAN to detect H5 in wastewater has been published in ACS Publications. Verily Principal Scientist Bradley White and team quickly developed an assay to detect H5 in wastewater samples in response to uncharacteristic spikes in Influenza A found in wastewater plants in Texas, near H5N1 outbreaks. Tests on wastewater samples revealed the presence of H5 in samples collected shortly before and during the reported cases. The study hypothesizes that H5 is entering municipal wastewater systems through effluent discharged by dairy cattle milk processing plants, which are located within the sewersheds. Our work suggests that wastewater testing can serve as a critical public health monitoring tool by detecting new and emerging pathogens and providing insights. Read more in the paper co-authored by researchers from Rollins School of Public Health at Emory University, Verily and Stanford University School of Engineering.
Our Chairman and CEO Stephen Gillett discussed Verily’s mission, products and commitment to advancing precision health with Newsweek Investment Reports as part of the annual “New Era of Life Sciences 2024 Report.” “Looking ahead, the integration of advanced AI capabilities into healthcare stands out as a significant opportunity for Verily.”
"There needs to be a culture of privacy and security, especially in healthcare," said Stephen Gillett, our Chairman and CEO, while on stage at Fortune Brainstorm Health with Bob Segert, Andrea Downing and moderator Andrew Nusca. Stephen also discussed lessons learned from the Change Healthcare breach, including the opportunities for partnerships between the public and private sectors. "Public private partnership will take average or below average security and make it good or great but don't try to do it all yourself."
This #ClinicalTrialsDay, we celebrate all that has been accomplished to advance medical research thanks to clinical trials and the people behind them. Through Verily Viewpoint, we support research sites and sponsors to make clinical trials more efficient and more representative. Our site clinical trial management system (CTMS) was purpose built for enterprise research sites, designed to digitize study protocols and eliminate siloed manual processes to enable more efficient research, higher-quality output and maximum research revenue. We are committed to supporting clinical trial innovation with these solutions. Thank you to all professionals and participants for your dedication to helping advance treatments and cures.
